Project Grant R01CA291796
Award Date
4/3/25
Completion Date
3/31/30
Dollars Obligated
$403K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant of $404,995 under the Cancer Treatment Research program (CFDA 93.395) to Cambium Oncology LLC, a biotech startup, to develop a novel immunotherapeutic drug to treat acute myeloid leukemia (AML). The project aims to advance the lead candidate drug, ANT308-FC3 fusion, through preclinical testing to support an Investigational New Drug (IND) application for a Phase 1 clinical trial in AML patients. Key objectives include evaluating the...
The National Cancer Institute (NCI) awarded a 5-year, $289,458 Project Grant (CFDA 93.398 - Cancer Research Manpower) to St. Jude Children's Research Hospital Inc. to conduct research aimed at improving CD19-targeted CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL). Specifically, the grant will fund:
A Phase I clinical trial evaluating an allogeneic CD19-CAR T-cell product using donor memory T-cells to minimize graft-versus-host-disease (Aim 1).
Correlative...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $780,389 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to generate and validate "stealth" versions of three genes (FLT3, KIT, and IL3RA) that can confer resistance to CAR-T cell and monoclonal antibody therapies targeting these targets in acute myeloid leukemia (AML). The goal is to allow targeting genes essential for AML survival...
This $1,013,623 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of dual-targeting allogeneic CAR T-cell therapies by March Biosciences Inc. for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The project aims to create CD5/CD7 CAR T-cells derived from haploidentical, CD45RA-depleted donor T-cells (RAD-T) that are resistant to...
This $400,000 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel pan-cancer chimeric antigen receptor T-cell (CAR-T) therapy targeting the MR1 antigen. The grant recipient, Kure Ai Inc., aims to assess the cell surface expression of MR1 in primary patient samples of acute myeloid leukemia (AML) and glioblastoma, evaluate the safety and efficacy of the MR1 CAR-T therapy in mouse models of these cancers,...
This $1,220,394 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports a comprehensive study of the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies.
The research aims to investigate the molecular mechanisms underlying immune effector cell-associated neurotoxicity syndrome (ICANS), a common neurological complication of CAR-T cell therapy, as well...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of The City of Hope to develop an innovative approach to enhance the efficacy and durability of CD19-targeted CAR T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The key elements of the project involve:
Selecting and modifying CMV-specific T cells with a CD19-targeting CAR, then infusing the bi-specific CMV-CD19 CAR T cells into...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $303,621 to the Sloan-Kettering Institute for Cancer Research in New York to support research aimed at understanding the mechanisms behind impaired immune responses in the bone marrow of patients with acute myeloid leukemia (AML). The key objectives are to: 1) determine intrinsic features of T cells that impact their phenotype, repertoire, and disease status in the AML...
The National Cancer Institute (NCI) awarded a $458,698 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Regents of the University of Michigan. The grant, titled "Genes Regulating Stem and Progenitor Cell Expansion and Relapse in Acute Myeloid Leukemia", aims to study novel genes that influence normal and leukemic stem/progenitor cell expansion, and their contributions to therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year project...
This $439,644 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports fundamental scientific investigations into the molecular and cellular mechanisms underlying acute myeloid leukemia (AML). The primary objectives are to: 1) investigate the relationship between specific mutations and leukemia stem cell frequency, disease initiation, and disease maintenance; 2) evaluate in vivo dynamics of individual AML stem cells using single-cell...